8-KEarnings & ResultsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Apr 26, 2005)

Filed April 26, 2005For Securities:VRTX

Summary

This 8-K filing by Vertex Pharmaceuticals Incorporated (VRTX) on April 26, 2005, announces the company's financial results for the first quarter ended March 31, 2005, and provides an update on its clinical development activities. The filing incorporates by reference a press release detailing these financial and operational updates, which is crucial for investors seeking to understand the company's performance and progress. Investors should note that this report primarily serves to disclose the Q1 2005 financial outcomes and recent clinical milestones. While the 8-K itself doesn't contain the detailed financial statements or clinical data, it directs readers to the attached press release (Exhibit 99.1) for comprehensive information. Therefore, the press release is the primary source of insight into Vertex's current financial condition and its pipeline advancements.

Key Highlights

  • 1Vertex Pharmaceuticals announced its Q1 2005 financial results via a press release filed with the 8-K.
  • 2The filing also includes an update on the company's clinical development progress during the first quarter of 2005.
  • 3The press release, dated April 26, 2005, is incorporated by reference as Exhibit 99.1.
  • 4This report is a disclosure of results of operations and financial condition under Item 2.02.
  • 5The information is furnished and not deemed 'filed' for the purposes of Section 18 of the Exchange Act.
  • 6The filing confirms the registrant's corporate information, including its incorporation in Massachusetts and principal executive offices in Cambridge.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly disclose Vertex Pharmaceuticals' consolidated financial results for the first quarter ended March 31, 2005, and to provide an update on its clinical development activities during that period.

The detailed financial results and clinical update are provided in the press release dated April 26, 2005, which is attached as Exhibit 99.1 to this 8-K filing and incorporated by reference.

No, in accordance with General Instruction B.2 of Form 8-K, the information in this Current Report and Exhibit 99.1 is furnished and shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be incorporated by reference into any other filing under the Securities Act or the Exchange Act, unless expressly stated otherwise.

This report covers the first quarter of 2005, which ended on March 31, 2005.